Who is sponsoring NCT07154875?

NCT07154875 is sponsored by Hoang Minh Ngan.

What drugs are being tested in NCT07154875?

Interventions in NCT07154875: Assisted Hatching.

What condition does NCT07154875 study?

NCT07154875 studies Infertility; In Vitro Fertilization; Embryo Development.

Is NCT07154875 still recruiting?

NCT07154875 is currently recruiting now. Last updated 5 September 2025.

Last reviewed 2025-09-05 · How we verify

NCT07154875: AH-PGTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Day-3 vs Day-5 Assisted Hatching: Impact on Blastocyst Morphology and PGT-A Outcomes

Recruiting now NA Last updated 5 September 2025

What this trial tests

NA trial testing Assisted Hatching in Infertility; In Vitro Fertilization; Embryo Development in 200 participants. Currently enrolling.

Timeline

14 June 2025

Primary endpoint
14 December 2026

14 June 2028

Quick facts

Lead sponsor	Hoang Minh Ngan
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	200
Start date	14 June 2025
Primary completion	14 December 2026
Estimated completion	14 June 2028
Sites	1 location across Vietnam

Drugs / interventions tested

Assisted Hatching

Conditions studied

Infertility; In Vitro Fertilization; Embryo Development — all drugs for Infertility; In Vitro Fertilization; Embryo Development →

Sponsor

Hoang Minh Ngan

Who can join

Adults 20 to 45, female only, with Infertility; In Vitro Fertilization; Embryo Development. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial evaluates the effect of assisted hatching (AH) timing on embryo development and genetic outcomes in in vitro fertilization (IVF) cycles with preimplantation genetic testing for aneuploidy (PGT-A). Eligible patients undergoing IVF with PGT-A will have embryos randomized to receive assisted hatching either on Day-3 or Day-5 of culture, prior to trophectoderm biopsy. The primary outcome is the rate of aneuploid blastocysts. Secondary outcomes include blastocyst morphology, expansion stage, and the correlation between morphology and genetic results. The study aims to determine whether earlier or later assisted hatching affects embryo viability and the accuracy of genetic testing. The trial will provide evidence to optimize laboratory protocols in IVF centers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07154875 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoang Minh Ngan
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07154875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing